Gregory Vidal, MD, PhD

Articles

PD-L1 Expression and IO Therapy in Lung and Breast Cancer

September 3rd 2022

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Using Molecular Testing to Guide Treatment Decisions

August 29th 2022

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Available Molecular Tests for Solid Tumors

August 29th 2022

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Practical Advice on the Management of TNBC

August 2nd 2022

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.

Addressing Unmet Needs in the Management of TNBC

August 2nd 2022

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.

Novel ADCs Under Investigation in Triple-Negative Breast Cancer

July 25th 2022

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Metastatic TNBC: Safety, Efficacy, and Quality of Life With Sacituzumab Govitecan

July 25th 2022

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

Clinical Scenario: mTNBC Treated With Chemotherapy Then Sacituzumab Govitecan

July 18th 2022

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

Perspectives on the Current Treatment Landscape of TNBC

July 18th 2022

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

Dr. Vidal on the Lasting Impact of the KATHERINE Trial in HER2-Positive Breast Cancer

July 7th 2022

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 4th 2020

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

December 4th 2019

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 15th 2019

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

November 4th 2019

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.